DrugPatentWatch Database Preview

Belinostat - Generic Drug Details

« Back to Dashboard

What are the generic sources for belinostat and what is the scope of belinostat patent protection?

Belinostat is the generic ingredient in one branded drug marketed by Spectrum Pharms and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Belinostat has fifty-nine patent family members in twenty-seven countries.

There are five drug master file entries for belinostat. One supplier is listed for this compound.

Summary for belinostat

International Patents:	59
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	5
Suppliers / Packagers:	1
Bulk Api Vendors:	83
Clinical Trials:	44
Patent Applications:	19
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for belinostat
DailyMed Link:	belinostat at DailyMed

Pharmacology for belinostat

Drug Class	Histone Deacetylase Inhibitor
Mechanism of Action	Histone Deacetylase Inhibitors

Synonyms for belinostat

(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide

(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide

(E)-3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acid

(E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide

(E)-N-Hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide

(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide

2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, (2E)-

2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-

414864-00-9

5OG

866323-14-0

A25012

AB0007889

ABP000140

AC-25046

AC1OCFO7

AK544325

AK546422

AKOS025401741

AN-1073

AOB87787

API0003555

AS-17068

AX8144528

BC251660

BCP01741

BCP9000386

BCPP000351

BDBM25150

Beleodaq

Beleodaq (TN)

Belinostat (PXD101)

Belinostat - PXD101

Belinostat (PXD101)

Belinostat (USAN/INN)

Belinostat [USAN:INN]

Belinostat Ph3

Belinostat,PXD101, PX105684

Belinostat(Random Configuration)

Belinostat/PXD101,PX105684/

BRD-K17743125-001-01-9

CCG-208758

CHEBI:61076

CHEBI:94531

CHEMBL408513

D08870

DB05015

DTXSID60194378

E-Belinostat

EX-A180

F4H96P17NZ

GTPL7496

J-523584

KB-74881

LS41098

MLS006011091

MolPort-009-679-433

N-Hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide

N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide

N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide

N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE

N-Hydroxy-3-(3-phenylsulphamoylphenyl)acrylamide

N-Hydroxy-3-[(phenylamino)sulfonyl]-trans-cinnamamide

N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]-2-propenamide

N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PR

N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE

NCGC00263155-05

NCNRHFGMJRPRSK-MDZDMXLPSA-N

NSC-726630

NSC726630

PubChem22405

PX 105684

PX-105684

PX105684

PX105684, 414864-00-9

PXD 101

PXD-101

PXD101

QCR-181

RL03602

RT-014445

s1085

SB16466

SC-71101

SMR004702879

SW219445-1

UNII-F4H96P17NZ

W-5363

ZINC3818726

US Patents and Regulatory Information for belinostat

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Spectrum Pharms	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes
Spectrum Pharms	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes
Spectrum Pharms	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes			Y
Spectrum Pharms	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes			Y	Y

International Patents for belinostat

Country	Patent Number	Estimated Expiration
Hong Kong	1110797
Ecuador	SP078002
Portugal	1328510
Australia	2006245495
China	101189003
New Zealand	535065